Saurabh Saha - Aug 20, 2024 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Aug 20, 2024
Transactions value $
-$102,546
Form type
4
Date filed
8/22/2024, 05:15 PM
Previous filing
Jul 2, 2024
Next filing
Aug 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Sale -$51.4K -4.17K -0.5% $12.32 828K Aug 20, 2024 Direct F1, F2, F3
transaction CNTA Ordinary Shares Sale -$45K -3.67K -0.44% $12.25 824K Aug 21, 2024 Direct F1, F2, F4
transaction CNTA Ordinary Shares Sale -$6.19K -506 -0.06% $12.23 824K Aug 22, 2024 Direct F1, F2
holding CNTA Ordinary Shares 38K Aug 20, 2024 By trust F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.